MET and cancer: Therefore, the suppression of phosphorylation of c-Met and the blockage of PI3K/Akt and NF-κB signaling pathways by the anticancer compounds could possibly inhibit the related downstream targets such as OPN, VEGF, MMP-9 and MMP-2, and thus suppress the cancer progression.